Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -3% Improvement Relative Risk Death/ICU -3% c19early.com/fm Shoaibi et al. Famotidine for COVID-19 LATE TREATMENT Favors famotidine Favors control
Shoaibi, 28,636 patient famotidine late treatment study: 3% higher mortality [p=0.67] and 3% higher combined mortality/ICU admission [p=0.62] https://c19p.org/shoaibif
copied to clipboard
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (preprint 9/24/2020)
24 Sep 2020    Source   PDF   Share   Tweet
Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment.
risk of death, 3.0% higher, RR 1.03, p = 0.67, treatment 1,816, control 26,820.
risk of death/ICU, 3.0% higher, RR 1.03, p = 0.62, treatment 1,816, control 26,820.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shoaibi et al., 9/24/2020, retrospective, database analysis, USA, North America, peer-reviewed, 5 authors.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit